Suppr超能文献

鞘脂与化疗反应

Sphingolipids and response to chemotherapy.

作者信息

Dimanche-Boitrel Marie-Thérèse, Rebillard Amélie

机构信息

Université de Rennes 1, Institut de Recherche Santé Environnement et Travail, Rennes, France.

出版信息

Handb Exp Pharmacol. 2013(216):73-91. doi: 10.1007/978-3-7091-1511-4_4.

Abstract

Chemotherapy is frequently used to treat primary or metastatic cancers, but intrinsic or acquired drug resistance limits its efficiency. Sphingolipids are important regulators of various cellular processes including proliferation, apoptosis, differentiation, angiogenesis, stress, and inflammatory responses which are linked to various aspects of cancer, like tumor growth, neoangiogenesis, and response to chemotherapy. Ceramide, the central molecule of sphingolipid metabolism, generally mediates antiproliferative and proapoptotic functions, whereas sphingosine-1-phosphate and other derivatives have opposing effects. Among the variety of enzymes that control ceramide generation, acid or neutral sphingomyelinases and ceramide synthases are important targets to allow killing of cancer cells by chemotherapeutic drugs. On the contrary, glucosylceramide synthase, ceramidase, and sphingosine kinase are other targets driving cancer cell resistance to chemotherapy. This chapter focuses on ceramide-based mechanisms leading to cancer therapy sensitization or resistance which could have some impacts on the development of novel cancer therapeutic strategies.

摘要

化疗常用于治疗原发性或转移性癌症,但内在或获得性耐药性限制了其疗效。鞘脂是各种细胞过程的重要调节因子,包括增殖、凋亡、分化、血管生成、应激和炎症反应,这些过程与癌症的各个方面相关,如肿瘤生长、新生血管生成和对化疗的反应。神经酰胺作为鞘脂代谢的核心分子,通常介导抗增殖和促凋亡功能,而1-磷酸鞘氨醇和其他衍生物则具有相反的作用。在控制神经酰胺生成的多种酶中,酸性或中性鞘磷脂酶和神经酰胺合酶是使化疗药物能够杀死癌细胞的重要靶点。相反,葡糖神经酰胺合酶、神经酰胺酶和鞘氨醇激酶是导致癌细胞对化疗产生耐药性的其他靶点。本章重点关注基于神经酰胺的导致癌症治疗敏感性或耐药性的机制,这些机制可能对新型癌症治疗策略的开发产生一些影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验